Trials / Terminated
TerminatedNCT03173430
Pilot Study of Blinatumomab in Combination With Salvage Autologous Stem Cell Transplantation for Patients With Refractory Multiple Myeloma
- Status
- Terminated
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 6 (actual)
- Sponsor
- Abramson Cancer Center at Penn Medicine · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study involves receiving blinatumomab after high-dose melphalan and ASCT for multiple myeloma. The main purpose of this study is to: - To determine whether blinatumomab is safe and feasible to administer after ASCT in patients with advanced multiple myeloma. - To assess how long multiple myeloma remains under control when blinatumomab is administered after second ASCT.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Blinatumomab | Blinatumomab (Blincyto), an anti-CD19/anti-CD3 bi-specific T cell engager |
Timeline
- Start date
- 2017-05-27
- Primary completion
- 2019-01-28
- Completion
- 2019-01-28
- First posted
- 2017-06-01
- Last updated
- 2020-02-07
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03173430. Inclusion in this directory is not an endorsement.